PARIS, France – Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results at the Myology 2024 international scientific congress, currently taking place in Paris. The trial combines phases...
treatment News
PRINCETON, N.J. — Professor Julia Scarisbrick of the University of Birmingham on Friday, April 12, 2024, presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSE: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the...
SYDNEY, Australia — Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY...
SHANGHAI, China — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is a single-arm, open-label, dose-escalation clinical...
LARKSPUR, Calif. — Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced dosing of the first patient in the initial Phase 2 expansion cohorts of its Phase 1/2 clinical trial evaluating AU-007 for treatment of unresectable locally advanced or metastatic...
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients. This phase 3 study, the first the evaluate avatrombopag in children, will evaluate efficacy, safety, and...
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients. This phase 3 study, the first the evaluate avatrombopag in children, will evaluate efficacy, safety, and...
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. The XTEND-Kids study is designed to investigate the efficacy, safety and pharmacokinetics of efanesoctocog alfa...
SYDNEY, Australia — Immutep Limited (formerly known as Prima Biomed), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt,...
PASADENA, CA — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian...